Skip to main content
Equibles
CADL logo

CADL · Candel Therapeutics, Inc. · Metrics

Track CADL — free

Use CADL with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research CADL.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$8.64 +0.43 (+5.24%) At close · Oct 20
Russell 2000 member Rebalance outlook locked
Market Cap
$661.12M
Shares
76.52M
Volume · Oct 20 1.13M Avg daily vol (3M) 1.17M

CADL metrics

78 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$8.64
Market cap
$661.12M

Price action

20 metrics
Price change (1W)
-6.8%
Price change (30D)
-22.9%
Price change (3M)
-15.5%
Price change (6M)
+23.4%
Price change (YTD)
+52.9%
Price change (1Y)
+56.0%
Trailing year
Price change (5Y)
-11.0%
52-week high
$13.75
52-week low
$4.42
Change from 52-week high
-37.2%
Change from 52-week low
+95.5%
Annualized volatility
70.0%
Annualized volatility (3M)
64.6%
Beta
1.9
RSI (14D)
33.0
Price vs SMA 50
-23.2%
Price vs SMA 200
+5.6%
Avg volume (3M)
1.17M
Relative volume
1.0
Average dollar volume
$12.87M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
76.52M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
4,632.3×
reciprocal yield 0.0%
EV / EBITDA
—
EV / EBIT
—
P / sales
5,289.0×
reciprocal yield 0.0%
P / book
5.2
reciprocal yield 19.1%
FCF yield
-8.7%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-13.4%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
32.5×
reciprocal yield 3.1%
EV / revenue historical average (5Y)
32.5×
reciprocal yield 3.1%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-05-20

Profitability

9 metrics
Gross margin
—
Operating margin
-27,777.6%
Trailing 12 months
Net margin
-15,035.2%
Gross profit (TTM)
—
Operating profit (TTM)
−$71.99M
Net income (TTM)
−$88.53M
Trailing 12 months
Diluted EPS (TTM)
$-1.42
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$0.00
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
$-1.17
EBITDA per diluted share (TTM)
$-1.22
Net income per diluted share (TTM)
$-1.45
Operating cash flow per diluted share (TTM)
$-0.92
Free cash flow per diluted share (TTM)
$-0.94
Capital expenditures per diluted share (TTM)
$0.02
R&D per diluted share (TTM)
$0.80
Stock compensation per diluted share (TTM)
$0.11
Book value per share
$0.95

Growth

11 metrics
Revenue growth YoY
+0.0%
Year over year
Net income growth YoY
—
Revenue (TTM)
$125,000
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+44.0%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-70.2%
Return on assets
-42.5%
Debt / equity
—
Current ratio
16.1
EBITDA (TTM)
−$35.35M
Free cash flow (TTM)
−$57.32M
Quick ratio
16.1
Interest coverage
-15.3
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$201.56M
Total assets
$208.15M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$56.02M
Capital expenditures (TTM)
$1.30M
R&D (TTM)
$49.13M
SG&A (TTM)
—
Stock compensation (TTM)
$6.76M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
138
13F filer change QoQ
+23
Institutional ownership
66.4%
Conviction holders (share of 13F filers)
1.5%
Crowding (high-turnover and private-fund holders)
25.1%
Private-fund adviser ownership
19.6%
Active holders' share change QoQ
+2.6%
Holder tenure
7.2
Price vs estimated holder cost
+62.5%

Ownership (registered funds)

1 metrics
Index-fund ownership
13.0%

Short interest

3 metrics
Short interest
17.0%
Latest settlement · 11.2 days to cover
Days to cover
11.2d
Short-squeeze score
75 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$3.24M
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1841387 CUSIP 137404109 13F (30d) 8 filings 8 filers Visit website Investor relations